Trials / Recruiting
RecruitingNCT03188874
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 15,000 (estimated)
- Sponsor
- Technische Universität Dresden · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia. Investigator's sites: 51 sites in Germany. Primary objectives: * Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry. * Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS) * Documentation of treatment strategy
Detailed description
see brief summary
Conditions
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2030-09-30
- Completion
- 2030-09-30
- First posted
- 2017-06-16
- Last updated
- 2024-04-18
Locations
51 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03188874. Inclusion in this directory is not an endorsement.